156 search results for “titel therapy” in the Staff website
-
Medical milestone at LUMC: first Dutch patient receives CAR T-cell therapy for autoimmune disease
The LUMC has become the first institution in the Netherlands to treat a patient with an autoimmune disease using CAR T-cell therapy.
-
Erica Bohnen
Faculty of Social and Behavioural Sciences
-
Advocating for gene therapies for rare diseases
‘If we don’t start talking about this, who else will?’ This is what Arjan Lankester, paediatrician/immunologist at the Leiden University Medical Center (LUMC) and Professor of Paediatrics, thought when it seemed that various extremely effective gene therapies for rare diseases would no longer be available…
-
Douwe Atsma -
Developing new therapies to fight muscle disease
Biophysicist Alireza Mashaghi and his collaborators are taking up the fight against muscular dystrophy: genetic disorders that cause muscle weakness. They want to inhibit the clumping of proteins that results in toxic aggregates. For this, the team receives 550,000 euros from Health Holland. The team…
-
Jessy Terpstra
Faculty of Social and Behavioural Sciences
-
Oncode Accelerator funds preclinical development of cancer therapies
Through its Demonstrator Projects, the Dutch Oncode Accelerator consortium provides grants for preclinical cancer therapy development. The first call for these projects is open until September 2025.
-
LUMC signs international agreement on developing Advanced Therapy Medicinal Products
Skåne University Hospital, Lund University and Leiden University Medical Center will work together to expand their research, teaching and development relating to Advanced Therapy Medicinal Products. That is the essence of a Memorandum of Understanding signed at SciLifeLab near Stockholm on Wednesday…
-
Cevdet Acarsoy -
LUMC will administer first Dutch stem cell gene therapy to patients
Researchers and clinicians at Leiden University Medical Centre (LUMC) are about to begin a milestone clinical study. It will be the first time a stem cell gene therapy developed in the Netherlands is used in a clinic. The therapy will be used to treat children with SCID, a rare disorder where children…
-
Master’s programme in Transfusion Medicine and Cellular and Tissue Therapies
LUMC and Leiden University will start the new two-year online master's program in Transfusion Medicine and Cellular and Tissue Therapies from October 2023.
-
patient in the Netherlands successfully treated with stem cell gene therapy
Researchers from the Leiden University Medical Center (LUMC) have successfully used stem cell gene therapy to treat a baby with the severe congenital immune disorder SCID. An important milestone: it is the first time stem cell gene therapy of Dutch origin has been administered to a patient, and also…
-
Rianne de KleineFaculty of Social and Behavioural Sciences
-
Marike KooistraFaculty of Social and Behavioural Sciences
-
Johanna Greeven
Faculty of Social and Behavioural Sciences
-
Thomas WillemsFaculty of Social and Behavioural Sciences
-
Danielle OprelFaculty of Social and Behavioural Sciences
-
Femke Stad
Faculty of Social and Behavioural Sciences
-
Katja CardolFaculty of Social and Behavioural Sciences
-
Bianca BoyerFaculty of Social and Behavioural Sciences
-
Mara van OschFaculty of Social and Behavioural Sciences
-
Judith Bovée -
Oana Georgiana Rus-OswaldFaculty of Social and Behavioural Sciences
-
Lioe-Fee de Geus-Oei -
Mona ShahabFaculty of Social and Behavioural Sciences
-
Veronica Janssen
Faculty of Social and Behavioural Sciences
-
Leiden scientists join national effort to advance nanomedicine
A Dutch consortium has received €6.7 million to accelerate the development of nanomedicines together with patients. Researchers from Leiden University play a key role in the project.
-
Willem van der DoesFaculty of Social and Behavioural Sciences
-
Nina KomrijFaculty of Social and Behavioural Sciences
-
Webinar Transfusion Medicine and Cellular and Tissue Therapies
Study information
-
Is a cancer pill a matter of time?
A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.
-
Philip SpinhovenFaculty of Social and Behavioural Sciences
-
Sylvestre Bonnet -
Eveline Bleiker -
John Haanen -
Rick Haas -
Alfred Vertegaal -
Jeroen Jansen -
Marjanka Schmidt -
Yvette van der Linden -
Joan Hendrik Veelken -
Thorbald van Hall -
J Morreau -
Jelle Wesseling -
Vincent Smit -
Jannie Keyser-Borst -
Hans Vasen -
Rob Pelger -
Piet Postmus -
Monique van Leerdam